default author photo

Chunxia Su

Tongji University - Department of Medical Oncology

No. 507, Zheng Min Road

Shanghai, Shanghai

China

  • Tongji University - Department of Medical Oncology

SCHOLARLY PAPERS

2

DOWNLOADS

95

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Exploratory Biomarker Analysis of PD-1/CTLA-4 Bispecific Antibody Therapy Response in PD-L1-Negative Advanced Non-Small Cell Lung Cancer: Genomic and Transcriptomic Profiling from the Phase II LungCadX Study

Number of pages: 35 Posted: 19 Aug 2025
Li Wang, Zhixuan Ren, Qi Wang, Li Liu, Shuai Lv, Minwei Bao, Tianqing Chu, Chuangzhou Rao, Jianing Chen, Tianlin Sun, Changbin Zhu, Jialin Qu and Chunxia Su
Tongji University, Fudan University - Huadong Hospital, Tongji University - Shanghai Pulmonary Hospital, Tongji University, University of South China, Tongji University, Shanghai Jiao Tong University (SJTU) - Shanghai Chest Hospital, University of Chinese Academy of Sciences, Tongji University, Amoy Diagnostics Co., Ltd., Amoy Diagnostics Co., Ltd., Qingdao University - Cancer Precision Medicine Center and Tongji University - Department of Medical Oncology
Downloads 66 (907,769)

Abstract:

Loading...

Non-small-cell lung cancer, PD-L1-negative, PD-1/CTLA-4 bispecific antibody, Patient-derived organoid, IFN-γ signaling pathway

2.

Efficacy and Safety of Immune Checkpoint Inhibitor with Chemotherapy for NRG1 Fusion-Positive Non-Small Cell Lung Cancer: A Multicenter Retrospective Investigation

Number of pages: 24 Posted: 09 Oct 2025
Xiyun Yan, Xiyan Fu, Zhanghui Long, Li Liu, Yuan-Sheng Zang and Chunxia Su
affiliation not provided to SSRN, Government of the People's Republic of China - Shanghai Changzheng Hospital, Government of the People's Republic of China - Shanghai Changzheng Hospital, Tongji University, Government of the People's Republic of China - Department of Medical Oncology and Tongji University - Department of Medical Oncology
Downloads 29 (1,332,057)

Abstract:

Loading...

NRG1 fusion-driven, Immune checkpoint inhibitors, Non-small cell lung cancer, Efficacy